Talking Medicines joins 2026 UK AI Index

Tern plc

Talking Medicines has been named in the 2026 UK AI Index, placing it among the top 1,000 AI companies in the country.

The company’s core offering focuses on converting unstructured healthcare dialogue into structured, actionable intelligence for pharmaceutical clients. By applying natural language processing and machine learning to patient and healthcare professional conversations, Talking Medicines helps pharma teams improve how they position medicines, understand brand performance and engage with clinicians. This use of real-world voice data offers a practical solution to the ongoing challenge of making sense of fragmented health communications.

Recognition by the UK AI Index gives Talking Medicines a stronger position within a national network of AI companies that are attracting attention from both investors and policymakers. The index is supported by government and industry groups aiming to map out leadership in artificial intelligence across sectors such as health, finance and energy.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Fundamental XR expands access to immersive training with web-enabled platform

Its new Immersive Web platform brings immersive training into the browser, lowering adoption barriers and broadening enterprise reach.

GLP-1 receptor agonists: Strategic market shift

Rapid uptake, evolving regulation and digital integration are reshaping the investment case for metabolic health therapies.

The Cyber Resilience Act forces a security reset for connected device makers

Device Authority helps manufacturers operationalise Cyber Resilience Act compliance through automated device identity and secure update management.

Pharmaceutical groups move closer to the consumer in strategic marketing reset

Pharmaceutical marketing is shifting towards direct consumer engagement, reshaping how companies compete and manage risk in a digital environment.

Changing clinician behaviour reshapes commercial strategy for 2026

As clinician engagement becomes more digital and measurable, companies that act on behavioural data can improve targeting, reduce risk and strengthen competitive positioning in 2026.

Tern Plc launches £384,408 Open Offer at 0.40p per share

Tern Plc has announced an Open Offer to raise up to £384,408 through the issue of up to 96,101,957 shares at 0.40p each, a 20% discount to the 12 February 2026 closing price.

Search

Search